1	Temporal analysis of the clinical evolution of confirmed cases of COVID-19 in the
2	state of Mato Grosso do Sul - Brazil
3	
4	Carolina Mariano Pompeo ^{1,4} ¶*, Marcos Antonio Ferreira Júnior ² ¶, Andréia Insabralde
5	de Queiroz Cardoso ^{2,4} ¶, Luciana Scarlazzari Costa ³ ¶, Mercy da Costa Souza ^{1,4} ¶, Felipe
6	Machado Mota ² ¶ and Maria Lúcia Ivo ⁴ ¶
7	
8	¹ Maria Aparecida Pedrossian University Hospital. Federal University of Mato Grosso
9	do Sul.
10	² Integrated Health Institute. Federal University of Mato Grosso do Sul.
11	³ Piracicaba Methodist University.
12	⁴ School of Medicine. Federal University of Mato Grosso do Sul.
13	
14	*Corresponding author:
15	E-mail; carolmpompeo@gmail.com (CMP)
16	
17	¶ All the authors contributed equally to this article.
18	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract

20 The objective was to analyze the evolution of confirmed cases of COVID-19 in the first 21 four months of the pandemic in Mato Grosso do Sul, a state in the Center-West region 22 of Brazil, as well as the factors related to the prevalence of deaths. This was an 23 observational study with a cross-sectional and time series design based on data from the 24 information system of the State Department of Health of Mato Grosso do Sul, Brazil. 25 The microdata from the epidemiological bulletin is open and in the public domain; 26 consultation was carried out from March to July 2020. The incidences were stratified 27 per 100,000 inhabitants. The cross-section study was conducted to describe COVID-19 28 cases, and the trend analysis was performed using polynomial regression models for 29 time series, with R-Studio software and a significance level of 5%. There was a 30 predominance of women among the cases, and of men in terms of deaths. The presence 31 of comorbidities was statistically related to mortality, particularly lung disease and 32 diabetes, and the mean age of the deaths was 67.7 years. Even though the macro-region 33 of the state capital, Campo Grande, had a higher number of cases, the most fatalities 34 were in the macro-region of Corumbá. The trend curve demonstrated discreet growth in 35 the incidence of cases between epidemiological weeks 11 and 19, with a significant 36 increase in week 20 throughout the state. The trend for COVID-19 in the state of Mato 37 Grosso do Sul was upward and regular, but there was an important and alarming 38 exponential increase. The health authorities should adopt the necessary measures to 39 enforce health precautions and encourage social distancing of the population so that 40 health services will be able to care for those afflicted by the disease, especially older 41 people, those with comorbidities, and vulnerable sectors of the population.

42 Keywords: Pandemics; Coronavirus; Respiratory tract diseases.

43

44 Introduction

The respiratory disease known as Coronavirus Disease 2019 (COVID-19) is 45 46 caused by the virus Severe Acute Respiratory Syndrome, Coronavirus 2 (SARS-CoV- $(2)^{1}$. CoVs are from the order *Nidovirales*, family *Coronaviridae* and subfamily 47 Coronavirinae. They are single-stranded RNA virus groups that can cause respiratory, 48 49 liver, gastrointestinal and neurological diseases in animal species and humans².

50 Historically, in 2003, the first major epidemic of the 21st century arose in China, 51 caused by the virus Severe Acute Respiratory Syndrome, Coronavirus (SARS-CoV), 52 subtypes of the virus Influenza A, which have also sparked epidemics around the world. 53 In 2014, the variation H5N1 was responsible for an epidemic in Asian countries and, in 2009, the first pandemic of the 21^{st} century occurred, caused by another variation of the 54 virus, H1N1. In 2012, the Middle East Respiratory Syndrome Coronavirus (MERS-55 CoV) gave rise to an epidemic that started in Saudi Arabia and spread to another 27 56 $countries^{2-4}$. 57

COVID-19 was first detected at the end of December 2019, in the city of Wuhan 58 59 in China, and was declared an international public health emergency on January 30, 60 2020. This marked the third highly pathogenic introduction of the coronavirus in humans in the 21^{st} century¹. 61

In Mato Grosso do Sul, a state located in the Center-West region of Brazil, the first 62 63 cases of COVID-19 were identified in the beginning of March 2020, and the first death occurred on the 31st of that same month. The first two confirmations were people who 64 65 had had contact with positive cases originating from the states of São Paulo and Rio de Janeiro. The first death in the state was a 64-year-old woman infected by the 66 coronavirus after having had contact with family members coming from Belgium^{5,6}. On 67

4

April 13, the first case of community transmission in the state was confirmed, and the
 number of cases has substantially increased since then⁷.

Various measures were recommended by the World Health Organization for
countries around the world to reduce increased dissemination of the COVID-19 virus⁸.
The transmission of respiratory pathogens, such as the coronavirus, depends on their
being transported by secretions transmitted between people in the form of aerosols,
droplets, or secretions, or by direct contact with mucosa^{1,9}.

75 The mortality rate for COVID-19 has still not been clearly determined, since it is 76 rising in most countries. However, it has already been proven that people with 77 comorbidities, such as cardiovascular diseases. diabetes. cancers and immunosuppression, in addition to older people, are at greater risk. The contagion rate 78 seems to vary among countries, which may be directly related to local health responses 79 for social isolation and care of the affected population 10 . 80

81 The rapid dynamics of the COVID-19 pandemic are a challenge and source of 82 concern for healthcare systems in different locations, especially emerging countries 83 such as Brazil, because fragile social and economic contexts may lead to underreporting 84 and make adequate management of the pandemic more difficult, which increases 85 uncertainties as to the dynamics of the disease¹¹.

Despite the implementation of measures and strategies to reduce the transmission of COVID-19, the number of cases is expected to rise in all the Brazilian states. There is a concern about the availability of intensive care unit beds and ventilator support for hospitalized patients, in addition to specific diagnostic tests in sufficient amounts to monitor the development of the disease¹².

91 Due to the epidemiological importance of COVID-19 for Brazil and the world, it is 92 necessary to ascertain the real situation of the pandemic in the Brazilian states in order

5

to provide support for the creation of guidelines and the decisions that need to be made.
Therefore, this study sought to analyze the temporal trend of confirmed cases of
COVID-19 in the first four months of the pandemic in Mato Grosso do Sul, a state in
the Center-West region of Brazil, and in its macro-regions, as well as the factors related
to the prevalence of deaths.

98

⁹⁹ Materials and Methods

100 This was an observational, time series study of confirmed cases of COVID-19 in 101 Mato Grosso do Sul, Brazil, in the first four months of the pandemic – a period that 102 spans the epidemiological weeks (EW) 11 to 28. The data was from an open database of 103 the State Department of Health of Mato Grosso, available in microdata from the 104 COVID-19 epidemiological bulletin. The population for calculating the incidence was 105 obtained through data from the Brazilian Institute of Geography and Statistics (IBGE) 106 from 2019. Both databases are in the public domain and do not require previous 107 consideration or authorization by a research ethics committee. The data was collected 108 between March and July 2020 and was tabulated on spreadsheets using Microsoft Excel 2010[®]. 109

In the statistical analysis, a cross-sectional study was first conducted with data from COVID-19 patients from the state of Mato Grosso do Sul that sought to describe the COVID-19 cases in the state according to situation/status of the disease and characteristics of the population.

A regression model was estimated to verify factors related to death/non-death, which in this case was considered as a dependent variable. The situation of the patients originally coded in the database as death, non-death, recovered or in home treatment were treated in a grouped manner for analysis purposes. Therefore two groups were

6

118 created – death and non-death – with the latter including those who recovered and those 119 in home treatment. The independent variables were sociodemographics, comorbidities, 120 and signs and symptoms of the disease. A total of 555 patients was excluded from the 121 sample, whose information was ignored, and 37 patients who were hospitalized.

The data was initially presented through descriptive statistics, absolute values, percentage, and mean, minimum and maximum values, according to the type of variable. Association tests were then performed using the chi-square or Fisher's exact test and the Student's t-test for comparison of means. Following this, the risk measurement and crude prevalence ratio were estimated, through univariate Poisson modeling, to assess the magnitude of the risk of death based on the characteristics of the study.

Last, the Poisson multiple regression model to verify the factors related to the prevalence of death among patients with COVID-19 was adjusted. In this model, the possible confounding variables were determined and possible interactions were tested (respiratory difficulties, pulmonary problems, sex and race).

133 Apart from the regression analysis, a trend analysis was performed in relation to EW 11 to 28 using polynomial regression models for time series. The dependent 134 135 variable refers to the COVID-19 incidence coefficients and the independent variable 136 refers to the epidemiological weeks. Temporal graphs were built for the coefficients, for 137 the state and macro-regions, to verify the possible format of the trend curve to be 138 studied. Next, polynomial regression models were estimated; first, the linear regression model was tested $(Y = \beta_0 + \beta_1 X)$ and then the more complex models, such as those of 139 the 2nd order $(Y = \beta_0 + \beta_1 X + \beta_1 X^2)$, 3rd order $(Y = \beta_0 + \beta_1 X + \beta_1 X^2 + \beta_1 X^3)$ and 140 exponential ($Y = \beta_0 e^{\beta_1 X}$). 141

7

142 The time variable (EW) was centralized to the mean point of the series to avoid 143 auto-correlations. The models were chosen according to their statistical significance, 144 residual analysis, and coefficient of determination (\mathbb{R}^2).

145 R-Studio statistical software with a significance level of 5% was used for all the 146 analyses.

147

148 **Results**

149 From the first confirmed case of COVID-19 in EW 11 until the end of EW 28, a 150 total of 14,092 cases was diagnosed, with an incidence of 507.09 per 100,000 151 inhabitants. The macro-region of Campo Grande, the most populous in the state, which 152 is home to the state capital, had the highest number of confirmations of the disease 153 (48%). However, the highest incidence was in the macro-region of Dourados with 154 688.24 cases per 100,000 inhabitants. The second highest incidence occurred in 155 Corumbá (488.96), followed by Campo Grande (445.45) and then Três Lagoas (309.21). 156 Among those diagnosed, approximately 93% were asymptomatic patients.

157 There was a higher number of infections among young adults in the age group of 158 30 to 39 years old (27.5%), and the highest number of deaths occurred among older 159 people (above 60 years old) in more than 70% of the case. In all the age groups, most 160 patients recovered from the disease. Of the total number of deaths, more than 85% of 161 the cases had at least one associated comorbidity, and almost half of the cases (48%) had two or more. The distribution of the cases according to health situation and age is 162 163 presented in Figure 1.

164

165 Figure 1: Distribution by age and situation of patients with COVID-19 in Mato 166 Grosso do Sul, Brazil, 2020.

8

Among the state's macro-regions, the highest fatality rate was 2.58 in Corumbá,
followed by 2.17 in Três Lagoas and 1.66 in Dourados; the lowest fatality rate was in
the macro-region of Campo Grande.

The variables corresponding to age, ethnic group, sex, macro-region, race, fever, sore throat, respiratory difficulties, number of symptoms, type of test for detecting COVID-19, pulmonary problems, diabetes, number of comorbidities, and occupation (whether a health professional or not) had a statistical relationship with the patients' situation. The groups of patients that died, and those that did not, were heterogeneous in relation to these characteristics. The breakdown of the data is presented in Table 1.

176

177 Table 1. Characteristics of the patients with confirmed cases of infection by

178 COVID-19 in Mato Grosso do Sul, SES/MS¹. Brazil, 2020 (n=14,092).

179

(n=14,092)	(n=221)		
	(11-441)	(n=13,871)	
38.4 (0.0 -	67.7 (25.0 -	37.9 (0.0 -	< 0.001 ²
102.0)	100.0)	102.0)	< 0.001-
404 (2.9)	0 (0.0)	404 (2.9)	< 0.001
716 (5.1)	0 (0.0)	716 (5.2)	
2,975 (21.1)	4 (1.8)	2,971 (21.4)	
3,877 (27.5)	9 (4.1)	3,868 (27.9)	
2,981 (21.1)	12 (5.4)	2,969 (21.4)	
1,879 (13.3)	35 (15.8)	1,844 (13.3)	
1,260 (8.9)	161 (72.9)	1,099 (7.9)	
6,719 (47.7)	125 (56.6)	6,594 (47.5)	0.009
7,373 (52.3)	96 (43.4)	7,277 (52.5)	
6,771 (48.0)	89 (40.3)	6,682 (48.2)	0.022
659 (4.7)	17 (7.7)	642 (4.6)	
5,785 (41.1)	96 (43.4)	5,689 (41.0)	
877 (6.2)	19 (8.6)	858 (6.2)	
953 (7.2)	7 (3.6)	946 (7.3)	0.019
7,204 (54.5)	94 (47.7)	7,110 (54.6)	
278 (2.1)	4 (2.0)	274 (2.1)	
4,302 (32.5)	84 (42.6)	4,218 (32.4)	
	102.0) $404 (2.9)$ $716 (5.1)$ $2,975 (21.1)$ $3,877 (27.5)$ $2,981 (21.1)$ $1,879 (13.3)$ $1,260 (8.9)$ $6,719 (47.7)$ $7,373 (52.3)$ $6,771 (48.0)$ $659 (4.7)$ $5,785 (41.1)$ $877 (6.2)$ $953 (7.2)$ $7,204 (54.5)$ $278 (2.1)$	102.0) 100.0) $404 (2.9)$ $0 (0.0)$ $716 (5.1)$ $0 (0.0)$ $2,975 (21.1)$ $4 (1.8)$ $3,877 (27.5)$ $9 (4.1)$ $2,981 (21.1)$ $12 (5.4)$ $1,879 (13.3)$ $35 (15.8)$ $1,260 (8.9)$ $161 (72.9)$ $6,719 (47.7)$ $125 (56.6)$ $7,373 (52.3)$ $96 (43.4)$ $6,771 (48.0)$ $89 (40.3)$ $659 (4.7)$ $17 (7.7)$ $5,785 (41.1)$ $96 (43.4)$ $877 (6.2)$ $19 (8.6)$ $953 (7.2)$ $7 (3.6)$ $7,204 (54.5)$ $94 (47.7)$ $278 (2.1)$ $4 (2.0)$	102.0) 100.0) 102.0) $404 (2.9)$ $0 (0.0)$ $404 (2.9)$ $716 (5.1)$ $0 (0.0)$ $716 (5.2)$ $2,975 (21.1)$ $4 (1.8)$ $2,971 (21.4)$ $3,877 (27.5)$ $9 (4.1)$ $3,868 (27.9)$ $2,981 (21.1)$ $12 (5.4)$ $2,969 (21.4)$ $1,879 (13.3)$ $35 (15.8)$ $1,844 (13.3)$ $1,260 (8.9)$ $161 (72.9)$ $1,099 (7.9)$ $6,719 (47.7)$ $125 (56.6)$ $6,594 (47.5)$ $7,373 (52.3)$ $96 (43.4)$ $7,277 (52.5)$ $6,771 (48.0)$ $89 (40.3)$ $6,682 (48.2)$ $659 (4.7)$ $17 (7.7)$ $642 (4.6)$ $5,785 (41.1)$ $96 (43.4)$ $5,689 (41.0)$ $877 (6.2)$ $19 (8.6)$ $858 (6.2)$ $953 (7.2)$ $7 (3.6)$ $946 (7.3)$ $7,204 (54.5)$ $94 (47.7)$ $7,110 (54.6)$ $278 (2.1)$ $4 (2.0)$ $274 (2.1)$

Black	487 (3.7)	8 (4.1)	479 (3.6)	
Signs/Symptoms, n (%)				
Fever				
Yes	781 (78.5)	138 (66.7)	643 (81.6)	<0.001
No	214 (21.5)	69 (33.3)	145 (18.4)	
Cough				
Yes	849 (84.1)	168 (80.8)	681 (85.1)	0.165
No	160 (15.8)	40 (19.2)	120 (14.9)	
Sore throat				
Yes	347 (36.7)	54 (28.0)	293 (38.9)	0.006
No	599 (63.3)	139 (72.0)	460 (61.1)	
Difficulty breathing				
Yes	663 (67.5)	157 (77.0)	506 (65.0)	0.001
No	319 (32.5)	47 (23.0)	272 (35.0)	
Number of symptoms	× /		× /	
None	13,078 (92.8)	10 (4.5)	13,068 (94.2)	<0.001
One or more	1,014 (7.2)	211 (95.5)	803 (5.8)	
Type of test				
RT-PCR	8,087 (57.6)	199 (90.0)	7,888 (57.1)	<0.001
Serology	135 (0.0)	0 (0.0)	135 (1.0)	
Quick test	5,806 (41.4)	22 (10.0)	5,784 (41.9)	
Comorbidities, n (%)	5,000 (11.1)	22 (10.0)	5,701(11.5)	
Pulmonary problem				
Yes	679 (71.1)	153 (77.3)	526 (69.5)	0.040
No	276 (28.9)	45 (22.7)	231 (30.5)	0.040
Kidney problem	270 (20.7)	13 (22.7)	251 (50.5)	
Yes	6 (1.8)	3 (2.9)	3 (1.3)	0.376
No	330 (98.2)	100 (97.1)	230 (98.7)	0.570
Weak immunity	550 (50.2)	100 (77.1)	230 (90.7)	
Yes	2 (0.0)	0 (0.0)	2 (0.9)	~1.000
No	333 (99.4)	103 (100.0)	230 (99.1)	1.000
Diabetes	555 (77.4)	105 (100.0)	230 (77.1)	
Yes	257 (58.7)	90 (66.7)	167 (55.1)	0.030
No	181 (41.3)	45 (33.3)	136 (44.9)	0.030
	101 (41.3)	45 (55.5)	130 (44.9)	
Immunosuppression Yes	23 (6.6)	8 (7.5)	15 (6.2)	0.841
No	, ,	99 (92.5)	226 (93.8)	0.041
	325 (93.4)	99 (92.3)	220 (95.8)	
Heart disease	226(54.0)	92((1,2))	154(50.9)	0.060
Yes	236 (54.0)	82 (61.2)	154 (50.8)	0.060
No Uista aista anno 19	201 (46.0)	52 (38.8)	149 (49.2)	
High-risk pregnancy	(17)	2	4 (1 4)	0.007
Yes	6 (1.7)	2 (2.7)	4 (1.4)	0.607
No	355 (98.3)	72 (97.3)	283 (98.6)	
Number of comorbidities				0.004
None	13,290 (94.3)	32 (14.5)	,	<0.001
One	494 (3.5)	83 (37.5)	411 (2.9)	
Two or more	308 (2.2)	106 (48.0)	202 (1.5)	
Health professional, n				
(%)		_ /= =:		A A A A
Yes	1,835 (13.0)	7 (3.2)	1,828 (13.2)	< 0.001

9

10

No	12,257 (86.9)	214 (86.8)	12,043 (86.8)	
Security team member, n (%)	, , ,	()	, ()	
Yes	198 (1.6)	0 (0.0)	198 (1.6)	~1.000
No	12,472 (98.4)	1 (0.0)	12,471 (98.4)	

180 ¹ SES/MS: State Department of Health of Mato Grosso do Sul

181 ² Mean comparison test (Student's test)

182

183 The characteristics that had statistically significant associations with the patient's 184 situation in the multiple context were age, classified into distribution quartiles, location of the patient (macro-region), and number of comorbidities, controlled by sex and 185 186 race/color. The interactions between respiratory difficulties and pulmonary problems 187 and between sex and race/color were tested, but did not reach statistical significance.

188 In relation to the factors associated with prevalence of death by COVID-19, the 189 prevalence was 13.34 times higher in the age group of 60 years old or more, compared 190 to the age group of 0 to 29 years (baseline), regardless of location and number of 191 comorbidities. Individuals with two or more associated comorbidities had 62.37 times 192 more risk of dying, compared to individuals without comorbidities, regardless of 193 location and age group (Table 2).

194

195

Table 2. Factors associated with prevalence of death by COVID-19 in patients with

- 196 confirmed cases in Mato Grosso do Sul, SES/MS¹. Brazil, 2020 (n=14.092).
- 197

Characteristics	β _{crude} (CI 95%)	PR _{crude} (CI 95%)	PR² adj (CI 95%)
Age, quartiles			
(years old)			
00 - 29		Baseline	
30 - 49	1.14 (0.18 - 2.37)	3.13 (1.19 - 10.74)	
50 - 59	2.94 (2.03 - 4.16)	19.07 (7.62 - 63.82)	5.24 (2.02 - 17.89)
60 or more	4.87 (4.01 - 6.05)	130.82 (55.39 - 425.05)	13.34 (5.36 - 33.66)
Macro-region			
Campo Grande		Baseline	
Corumbá	0.67 (0.12 - 1.16)	1.96 (1.12 - 3.21)	2.46 (1.39 - 4.08)

medRxiv preprint doi: https://doi.org/10.1101/2020.09.21.20198812; this version posted September 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 11 Dourados 0.23(-0.05 - 0.52)1.26 (0.94 - 1.68) 1.41 (1.03 - 1.93) Três Lagoas 0.49(-0.02 - 0.97)1.65 (0.97 - 2.64) 1.81 (1.03 - 3.02) Number of comorbidities None Baseline One 4.24 (3.85 - 4.67) 69.78 (46.91 - 106.38) 42.73 (26.43 - 71.63) 4.96 (4.58 - 5.37) 62.37 (38.52 - 105.06) Two or more 142.93 (97.48 - 215.54) ¹SES/MS: State Department of Health of Mato Grosso do Sul 198 199 ² Prevalence Ratio obtained through the Poisson regression model, adjusted by sex and 200 race 201 202 Figure 2 presents the growth curves of the COVID-19 incidence coefficients in 203 Mato Grosso do Sul and the state's macro-regions, in the period encompassing 204 epidemiological weeks 11 to 18. Growth was similar among the regions until week 20, 205 after which time the curves were different between the regions, particularly the 206 Dourados region, which had higher incidences from that time on and then dropped off at 207 week 26. 208 209 Figure 2: Evolution of cases of COVID-19, by macro-region and epidemiological 210 week 211 212 The overall coefficient for incidence and death remained stable and had similar 213 curves until week 19. Starting at week 20, a distance opened up between them, with an 214 increase in the overall incidence coefficient (Figure 3).

215

Figure 3: Evolution of cases and deaths by COVID-19, in Mato Grosso do Sul,
Brazil.

12

222	Table 3. Analysis of the trend in the number of cases of COVID-19 according to
221	
220	All the models were statistically significant with coefficients of determinants over 0.85.
219	coefficients in the state of Mato Grosso do Sul and its macro-regions for EW 11 to 28.
218	Table 3 and Figure 4 present the results of trend analysis for COVID-19 incidence

223 macro-region, micro-region, sex, age group and comorbidities, SES/MS¹. Brazil,

224 2020 (n=14.092).

225

Characteristics	Model	β0	β1	β2	β3	\mathbf{R}^2	p _{model}
Macro-region							
Campo Grande	Exponential	5.86	0.37			0.94	<0.001
Dourados	Polynomial	23.81	12.38	0.56	0.09	0.91	<0.001
Corumbá	Polynomial	4.01	3.43	0.94	0.07	0.98	<0.001
Três Lagoas	Polynomial	2.40	n.s.	0.71	0.10	0.87	<0.001
Mato Grosso do Sul	Polynomial	8.36	4.70	0.78	0.04	0.99	<0.001

 R^2 : Coefficient of determination 226

227 n.s.: not significant

228 ¹ State Department of Health of Mato Grosso do Sul

229

230 Figure 4: Values observed and estimated by the trend models for COVID-19

231 incidence coefficients in the macro-regions of Mato Grosso do Sul, Brazil.

232

233 **Discussion**

This study examined the incidence, characteristics and temporal evolution of 234 235 COVID-19 cases in Mato Grosso do Sul, Brazil, in epidemiological weeks 11 to 28. 236 Even though the data indicated a substantial number of recovered cases, among the more serious cases of the disease, 222 (1.57%) ended in death. Of these, the majority 237

13

had at least one associated comorbidity or involved people over 60 years old, with or
 without associated chronic diseases^{13,14}.

In addition, the presence of one and, mainly, two or more comorbidities were independent risk factors for death, similar to that observed in the international context of the pandemic¹⁵⁻¹⁷

Among the comorbidities found, pulmonary disease and diabetes had an association with the occurrence of deaths, which is consistent with increased risk of mortality in patients with these comorbidities observed in other studies^{17,18}.

246 There was a higher number of deaths among men, even though the incidence of 247 cases was higher among women. Studies conducted during this pandemic and in other 248 SARS pandemics have also indicated more serious evolution of the disease among men and associations with more deaths among these cases^{18,19.} The higher fatality rate noted 249 250 among the brown race was also confirmed in Brazil's North region, where this rate was 251 found to be higher among brown and black individuals, which may be related to 252 differences in susceptibility to COVID-19 and access to adequate health care by this segment of the population 20,21 . 253

The signs and symptoms manifested by patients, such as fever and respiratory difficulties, were associated with higher mortality. The clinical manifestations of COVID-19 appear to vary from region to region²², although the most frequent ones in symptomatic patients have been found to be fever and fatigue, and the most common complications have been pneumonia and respiratory insufficiency^{23,24}.

The higher distribution of the disease in the macro-region of Dourados may be due to population density, as well as the extensive territory of the region's main city, which often results in the need to commute by public transportation, and the presence of work locations with large numbers of people on production lines, such as meatpacking plants

- factors that favor dispersion and, consequently, viral contamination²⁵. Of the most 263 264 important cities in Mato Grosso do Sul, economically and population-wise, three stand 265 out as at high risk for COVID-19 and account for approximately 44% of the state's population: Campo Grande, Dourados and Três Lagoas²⁶. 266

267 Although the incidence of cases was higher in the macro-region of Dourados, the 268 largest proportion of deaths occurred in the region of Corumbá, which had a mortality 269 rate of 2.58% and a statistically significant relationship among the regions. This index 270 exceeded the calculated estimate for COVID-19 in China, where the mortality rate was $1.4\%^{27}$, but was lower than the overall mortality rate of 6.52% in Mexico²⁸. There are 271 272 still many uncertainties and unknowns in relation to the viral mortality of COVID-19, since it is related to other factors²⁹. 273

274 In terms of the evolution of cases, the data seems to suggest a growing and regular 275 trend throughout the state, with a more significant increase after EW 20, the period that 276 coincides with the start of winter in the Center-West region and, consequently, a period of higher transmission of respiratory diseases 30 . 277

278 There was also a statistically significant association in all the macro-regions of 279 Mato Grosso do Sul, which enables the inference that the curve for COVID-19 is far 280 from flattening, and may experience substantial and alarming growth. A mathematical 281 model study conducted by researchers at the Federal University of Mato Grosso do Sul³¹ pointed out the exponential growth of the disease infection curve between the 282 283 months of August and September, with probable collapse of the public health system if mitigation measures are not taken by managers 32 . 284

285 Understanding the dynamics of the disease and its ecological evidence and 286 evolution worldwide are important factors for developing epidemiological perception 287 and analysis of the impacts 26,29. Therefore, this study sought to operate within this

15

context, in order to contribute to a more complete picture of the epidemiological 288 289 situation of COVID-19 in Brazil, and consequently in the world, in order to assist the 290 scientific community and health managers with decision-making. One of the limitations 291 of this study, similar to others with cross-sectional designs that use secondary data, is 292 related to the time of the outcomes with regard to COVID-19 in the population, since 293 there may be underestimation of real data due to underreporting and the presence of 294 non-symptomatic carriers, in addition to the reality of the organization of local health 295 services.

296

297 Conclusion

298 The trend in relation to COVID-19 is growing and regular throughout the state of 299 Mato Grosso do Sul, rising significantly after EW 20. This suggests that the state is far 300 from flattening the curve, which has manifested exponential, substantial and alarming 301 growth.

302 Health authorities must adopt appropriate measures to support health precautions 303 and promote social distancing among the population in order to enable health services to 304 care for those infected by the disease. Health actions need to especially target vulnerable 305 groups and male patients due to their tendency toward higher mortality. Care should be 306 reinforced among elderly people with comorbidities, as well as individuals in groups 307 that are at risk of developing more serious forms of the disease.

308

309 Acknowledgment

310 The authors are grateful for the commitment and dedication of all professionals at 311 the Maria Aparecida Pedrossian University Hospital of the Federal University of Mato

312 Grosso do Sul in combating this serious crisis and to the employees of the State 313 Department of Health of Mato Grosso do Sul - Brazil, for maintaining an open and 314 comprehensive database for research.

315

316 References

317 1. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin,

318 transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-

319 an update on the status. Mil Med Res. 2020;7(1):1-10.

320 Hui DS. Epidemic and emerging coronaviruses (severe acute respiratory 2.

321 syndrome and Middle East respiratory syndrome). Clin Chest Med. 2017;38(1):71-86.

322 Sims L, Domenech J, Benigno C, Kahn S, Kamata A, Lubroth J, et al. Origin 3. 323 and evolution of highly pathogenic H5N1 avian influenza in Asia. Vet Rec. 324 2005;157(6):159-64.

325 4. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-326 origin H1N1 influenza virus. Nature. 2009;459(7249):931-9.

327 Secretaria de estado de saúde de Mato Grosso do Sul. Secretaria de Saúde 5. 328 registra primeira morte pelo coronavírus em Mato Grosso do Sul Mato Grosso do 329 Sul2020 [cited] 2020 2020]. Available 23 from: aug 330 https://www.coronavirus.ms.gov.br/?p=586.

331 Secretaria de estado de saúde de Mato Grosso do Sul. Secretaria de Saúde 6. 332 confirma dois casos de coronavírus em Mato Grosso do Sul Mato Grosso do Sul2020 333 [cited 2020 15 aug 2020]. Available from: http://www.ms.gov.br/secretaria-de-saude-334 confirma-dois-casos-de-coronavirus-em-mato-grosso-do-sul/.

17

335	7. Secretaria de estado de saúde de Mato Grosso do Sul. Boletim epidemiológico
336	COVID-19 Mato Grosso do Sul2020 [cited 2020 15 aug 2020]. Available from:
337	http://www.ms.gov.br/wp-content/uploads/sites/150/2020/04/Boletim-
338	Epidemiol%C3%B3gico-COVID-19-2020.04.13.pdf.
339	8. World Heatlh Organization. 2019-nCoV outbreak is an emergency of
340	international concern Genebra2020 [cited 2020 25 jul 2020]. Available from:
341	http://www.euro.who.int/en/health-topics/health-emergencies/international-health-
342	regulations/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-
343	concern.
344	9. Otter J, Donskey C, Yezli S, Douthwaite S, Goldenberg S, Weber D.
345	Transmission of SARS and MERS coronaviruses and influenza virus in healthcare

346 settings: the possible role of dry surface contamination. J Hosp Infect. 2016;92(3):235-347 50.

348 Triggle CR, Bansal D, Abd Farag EAB, Ding H, Sultan AA. COVID-19: 10. 349 Learning from Lessons To Guide Treatment and Prevention Interventions. Msphere. 350 2020;5(3):1-13.

351 Reis RF, de Melo Quintela B, de Oliveira Campos J, Gomes JM, Rocha BM, 11. 352 Lobosco M, et al. Characterization of the COVID-19 pandemic and the impact of 353 uncertainties, mitigation strategies, and underreporting of cases in South Korea, Italy, 354 and Brazil. Chaos Solitons Fractals. 2020:109888.

355 Croda J, Oliveira WKd, Frutuoso RL, Mandetta LH, Baia-da-Silva DC, Brito-12. 356 Sousa JD, et al. COVID-19 in Brazil: advantages of a socialized unified health system 357 and preparation to contain cases. Rev Soc Bras Med Trop. 2020;53.

358	13.	de Souza	WM,	Buss I	LF, c	la Silva	Candido	D,	Carrera	J-P	, Li	S, Z	Larebski	AE,	et
-----	-----	----------	-----	--------	-------	----------	---------	----	---------	-----	------	------	----------	-----	----

- 359 al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil.
- 360 Nat Hum Behav. 2020:1-9.
- 361 14. Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R, et
 362 al. Characteristics and outcomes of a cohort of COVID-19 patients in the Province of
- 363 Reggio Emilia, Italy. PloS one. 2020;15(8):e0238281.
- 364 15. Imam Z, Odish F, Gill I, O'Connor D, Armstrong J, Vanood A, et al. Older age
- and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-
- 366 19 patients in Michigan, United States. J Intern Med. 2020.
- 367 16. Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk
- 368 factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a
- 369 systematic review and meta-analysis of observational studies. Aging Male. 2020:1-9.
- 370 17. Bajgain KT, Badal S, Bajgain BB, Santana MJ. Prevalence of comorbidities
 371 among individuals with COVID-19: A rapid review of current literature. Am J Infect
 372 Control. 2020:1-9.
- 373 18. Stawicki SP, Jeanmonod R, Miller AC, Paladino L, Gaieski DF, Yaffee AQ, et
- al. The 2019–2020 novel coronavirus (severe acute respiratory syndrome coronavirus 2)
- 375 pandemic: A joint american college of academic international medicine-world academic
- council of emergency medicine multidisciplinary COVID-19 working group consensus
 paper. J Glob Infect Dis. 2020;12(2):47-93.
- Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender differences in
 patients with COVID-19: Focus on severity and mortality. Front Public Health.
 2020;8:152.
- 381 20. Ribeiro H, Lima VM, Waldman EA. In the COVID-19 pandemic in Brazil, do
 382 brown lives matter? Lancet Glob Health. 2020;8(8):e976-e7.

Baqui P, Bica I, Marra V, Ercole A, van Der Schaar M. Ethnic and regional 383 21. 384 variations in hospital mortality from COVID-19 in Brazil: a cross-sectional 385 observational study. Lancet Glob Health. 2020:e1018-e26.

386 22. Hashmi HAS, Asif HM. Early Detection and Assessment of Covid-19. Frontiers 387 in medicine. 2020;7:311.

388 23. Jutzeler CR, Bourguignon L, Weis CV, Tong B, Wong C, Rieck B, et al. 389 Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, 390 treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A 391 systematic review and meta-analysis. Travel Med Infect Dis. 2020:1-32.

392 24. Iftimie S, López-Azcona AF, Vicente-Miralles M, Descarrega-Reina R, 393 Hernández-Aguilera A, Riu F, et al. Risk factors associated with mortality in 394 hospitalized patients with SARS-CoV-2 infection. A prospective, longitudinal, 395 unicenter study in Reus, Spain. PloS one. 2020;15(9):e0234452.

396 Leiva GdC, Sathler D, Orrico Filho RD. Estrutura urbana e mobilidade 25. 397 populacional: implicações para o distanciamento social e disseminação da Covid-19. 398 Rev bras estud popul. 2020;37:1-22.

399 26. Silva MHSd, Raoul MD, Cabrero DRO. Análise sobre risco e vulnerabilidade à 400 COVID-19 no estado de Mato Grosso do Sul. Hygeia. 2020;0(0):164-74.

401 Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. 27.

402 Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan,

403 China. Nat Med. 2020;26(4):506-10.

404 28. Mendez-Dominguez N, Alvarez-Baeza A, Carrillo G. Demographic and Health 405 Indicators in Correlation to Interstate Variability of Incidence, Confirmation, 406 Hospitalization, and Lethality in Mexico: Preliminary Analysis from Imported and

20

407 Community Acquired Cases during COVID-19 Outbreak. Int J Environ Res Public
408 Health. 2020;17(12):4281.

409 29. Van Damme W, Dahake R, Delamou A, Ingelbeen B, Wouters E, Vanham G, et 410 al. The COVID-19 pandemic: diverse contexts; different epidemics-how and why? 411 BMJ Glob Health. 2020;5(7):e003098. 412 30. Alonso WJ, Schuck-Paim C, Freitas ARR, Kupek E, Wuerzius CR, Negro-Calduch E, et al. Covid-19 em contexto: comparação com a mortalidade mensal por 413 414 causas respiratórias nos estados brasileiros. InterAm J Med Healt. 2020;3:1-21. 415 31. Saraiva E, Sauer L. Estudo matemático mostra que casos da Covid-19 no MS 416 dobram a cada 12 dias. Universidade Federal de Mato Grosso do Sul, Campo Grande, 417 MS. 2020 [cited 2020 23 aug 2020]. Available from: https://www.ufms.br/estudomatematico-mostra-que-casos-da-covid-19-no-ms-dobram-a-cada-12-dias/. 418 419 32. Wang Y, Tian H, Zhang L, Zhang M, Guo D, Wu W, et al. Reduction of 420 secondary transmission of SARS-CoV-2 in households by face mask use, disinfection

421 and social distancing: a cohort study in Beijing, China. BMJ Glob Health.

422 2020;5(5):e002794.







